AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 81 min read$TLRY

Tilray Brands, Inc. Q1 2027: Revenue $257.1M, EPS $(0.32) — 10-Q Summary

Tilray Brands reported Q1 2027 revenue of $257.1M, up 23% YoY, but a net loss of $43.1M and EPS of $(0.32). Growth was driven by beverage expansion and EMEA strength, while cannabis revenue declined 13%. The company attributed changes to the BrewDog acquisition and strategic shifts.

Original reporting
tradingview.com
Published Oct 8, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray Brands, Inc. Q1 2027: Revenue $257.1M, EPS $(0.32) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$TLRYBearishMed
01

Why it matters

The earnings miss and widened loss are likely to trigger a sell‑off in TLRY and may influence sentiment toward peer cannabis companies.

02

Market read

New earnings numbers introduce fresh risk for TLRY and may affect the broader cannabis sector.

03

What to watch

Higher‑margin flower redirection to international markets may improve future profitability.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Tilray Brands filed its Form 10‑Q for the quarter ended Aug 31 2026, providing the first public disclosure of its latest earnings.

Company-level read

Ticker impact

$TLRYBearishHigh confidence
Context

Tilray reported Q1 results with revenue $257.1M, net loss $43.1M and diluted EPS -$0.32.

Expected impact

likely downside as the market prices in the larger loss

Evidence & confidence

The loss is substantially larger than the prior year‑ago quarter, and revenue growth is driven by non‑core beverage segment.

Market effects

Sector

Cannabis sector may face broader pressure from Tilray's widening loss.

Regional

North American cannabis stocks could see short‑term weakness.

Global

Limited to investors tracking the global cannabis industry.

Counterpoint

What could challenge this read

The beverage expansion could signal a new growth engine that offsets cannabis headwinds.

Key entities

  • company
    Tilray Brands, Inc.

    US‑listed cannabis and beverage company reporting Q1 2027 results.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min